Product Code: A03216
Opioids are pain relievers because they include substances that relax muscles and alleviate pain and stress. Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea. Hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are among them. Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain. These analgesics are used to treat severe continuous pain in individuals with terminal conditions and to manage pain in cancer patients.
The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain. Furthermore, rise in disposable income and surge in geriatric population are expected to propel the growth of the global opioids market. However, emergence and legalization of cannabis as an alternative to opioids impede the growth of the market. On the contrary, increase in consumption of opioids analgesic for pain management in developing countries is anticipated to create lucrative opportunities for market expansion in the near future.
The opioids market is segmented on the basis of type of product, application, and region. According to type of product, the market is classified into codeine, fentanyl, oxycodone, methadone, morphine, hydrocodone, and others. On the basis of application, the market is divided into pain management, cough treatment, and diarrhea treatment. The pain management segment is further divided into neuropathic pain, migraine, back pain, osteoarthritis pain, and cancer pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include: Purdue Pharma LP, AstraZeneca Plc., C.H. Boehringer Sohn Ag and Ko. Kg, Johnson and Johnson Inc., Sanofi S.A, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Pfizer, Inc., Sun Pharmaceuticals, and Teva Pharmaceuticals.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioids market analysis from 2020 to 2030 to identify the prevailing opioids market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the opioids market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global opioids market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
- Pain Management
- Cough Treatment
- Diarrhea Treatment
By Product Type
- Methadone
- Codeine
- Fentanyl
- Oxycodone
- Morphine
- Hydrocodone
- Others
By Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- India
- South Korea
- Rest Of Asia Pacific
- Japan
- China
- Australia
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Teva Pharmaceutical Industries Limited
- Purdue Pharma LP
- AstraZeneca Plc
- C.H. Boehringer Sohn Ag and Ko. Kg
- Johnson & Johnson, Inc..
- Sanofi S.A.
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals Inc
- Pfizer, Inc.
- Sun Pharmaceuticals
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.COVID-19 Ipact Analysis
CHAPTER 4: OPIOIDS MARKET, BY PRODUCT TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Methadone
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Codeine
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Fentanyl
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Oxycodone
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Morphine
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- 4.7 Hydrocodone
- 4.7.1 Key market trends, growth factors and opportunities
- 4.7.2 Market size and forecast, by region
- 4.7.3 Market analysis by country
- 4.8 Others
- 4.8.1 Key market trends, growth factors and opportunities
- 4.8.2 Market size and forecast, by region
- 4.8.3 Market analysis by country
CHAPTER 5: OPIOIDS MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Pain Management
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Cough Treatment
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Diarrhea Treatment
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
CHAPTER 6: OPIOIDS MARKET, BY REGION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Product Type
- 6.2.3 North America Market size and forecast, by Application
- 6.2.4 North America Market size and forecast, by country
- 6.2.4.1 U.S.
- 6.2.4.1.1 Market size and forecast, by Product Type
- 6.2.4.1.2 Market size and forecast, by Application
- 6.2.4.2 Canada
- 6.2.4.2.1 Market size and forecast, by Product Type
- 6.2.4.2.2 Market size and forecast, by Application
- 6.2.4.3 Mexico
- 6.2.4.3.1 Market size and forecast, by Product Type
- 6.2.4.3.2 Market size and forecast, by Application
- 6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Product Type
- 6.3.3 Europe Market size and forecast, by Application
- 6.3.4 Europe Market size and forecast, by country
- 6.3.4.1 Germany
- 6.3.4.1.1 Market size and forecast, by Product Type
- 6.3.4.1.2 Market size and forecast, by Application
- 6.3.4.2 France
- 6.3.4.2.1 Market size and forecast, by Product Type
- 6.3.4.2.2 Market size and forecast, by Application
- 6.3.4.3 U.K.
- 6.3.4.3.1 Market size and forecast, by Product Type
- 6.3.4.3.2 Market size and forecast, by Application
- 6.3.4.4 Italy
- 6.3.4.4.1 Market size and forecast, by Product Type
- 6.3.4.4.2 Market size and forecast, by Application
- 6.3.4.5 Spain
- 6.3.4.5.1 Market size and forecast, by Product Type
- 6.3.4.5.2 Market size and forecast, by Application
- 6.3.4.6 Rest of Europe
- 6.3.4.6.1 Market size and forecast, by Product Type
- 6.3.4.6.2 Market size and forecast, by Application
- 6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Product Type
- 6.4.3 Asia-Pacific Market size and forecast, by Application
- 6.4.4 Asia-Pacific Market size and forecast, by country
- 6.4.4.1 Japan
- 6.4.4.1.1 Market size and forecast, by Product Type
- 6.4.4.1.2 Market size and forecast, by Application
- 6.4.4.2 China
- 6.4.4.2.1 Market size and forecast, by Product Type
- 6.4.4.2.2 Market size and forecast, by Application
- 6.4.4.3 Australia
- 6.4.4.3.1 Market size and forecast, by Product Type
- 6.4.4.3.2 Market size and forecast, by Application
- 6.4.4.4 India
- 6.4.4.4.1 Market size and forecast, by Product Type
- 6.4.4.4.2 Market size and forecast, by Application
- 6.4.4.5 South Korea
- 6.4.4.5.1 Market size and forecast, by Product Type
- 6.4.4.5.2 Market size and forecast, by Application
- 6.4.4.6 Rest Of Asia Pacific
- 6.4.4.6.1 Market size and forecast, by Product Type
- 6.4.4.6.2 Market size and forecast, by Application
- 6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Product Type
- 6.5.3 LAMEA Market size and forecast, by Application
- 6.5.4 LAMEA Market size and forecast, by country
- 6.5.4.1 Brazil
- 6.5.4.1.1 Market size and forecast, by Product Type
- 6.5.4.1.2 Market size and forecast, by Application
- 6.5.4.2 Saudi Arabia
- 6.5.4.2.1 Market size and forecast, by Product Type
- 6.5.4.2.2 Market size and forecast, by Application
- 6.5.4.3 South Africa
- 6.5.4.3.1 Market size and forecast, by Product Type
- 6.5.4.3.2 Market size and forecast, by Application
- 6.5.4.4 Rest of LAMEA
- 6.5.4.4.1 Market size and forecast, by Product Type
- 6.5.4.4.2 Market size and forecast, by Application
CHAPTER 7: COMPANY LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Key developments
CHAPTER 8: COMPANY PROFILES
- 8.1 Teva Pharmaceutical Industries Limited
- 8.1.1 Company overview
- 8.1.2 Company snapshot
- 8.1.3 Operating business segments
- 8.1.4 Product portfolio
- 8.1.5 Business performance
- 8.1.6 Key strategic moves and developments
- 8.2 Purdue Pharma LP
- 8.2.1 Company overview
- 8.2.2 Company snapshot
- 8.2.3 Operating business segments
- 8.2.4 Product portfolio
- 8.2.5 Business performance
- 8.2.6 Key strategic moves and developments
- 8.3 AstraZeneca Plc
- 8.3.1 Company overview
- 8.3.2 Company snapshot
- 8.3.3 Operating business segments
- 8.3.4 Product portfolio
- 8.3.5 Business performance
- 8.3.6 Key strategic moves and developments
- 8.4 C.H. Boehringer Sohn Ag and Ko. Kg
- 8.4.1 Company overview
- 8.4.2 Company snapshot
- 8.4.3 Operating business segments
- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
- 8.5 Johnson & Johnson, Inc..
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
- 8.6 Sanofi S.A.
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
- 8.7 Mallinckrodt Pharmaceuticals
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
- 8.8 Endo Pharmaceuticals Inc
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
- 8.9 Pfizer, Inc.
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
- 8.10 Sun Pharmaceuticals
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments